Global RNA Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The RNA Therapeutics Market size is expected to reach USD 34.87 Billion in 2034 from USD 20.89 Billion (2025) growing at a CAGR of 5.86% during 2026-2034.

The Global RNA Therapeutics Market is experiencing transformative growth driven by breakthroughs in molecular biology and personalized medicine. RNA-based treatments, including mRNA vaccines and RNA interference therapies, have gained widespread recognition following successful vaccine developments. Pharmaceutical companies are increasingly investing in RNA platforms to address rare diseases, oncology indications, and genetic disorders, fueling substantial market expansion.

Growth drivers include rising prevalence of chronic diseases, technological advancements in delivery systems, and supportive regulatory frameworks. Increasing research funding and strategic collaborations between biotech firms and pharmaceutical giants are accelerating pipeline development. The demonstrated success of mRNA technology has strengthened investor confidence and encouraged broader therapeutic applications across multiple disease categories.

Looking ahead, continuous innovation in RNA stabilization and targeted delivery mechanisms will unlock new treatment possibilities. Expansion of clinical trials and regulatory approvals is expected to further validate RNA-based solutions. As precision medicine gains prominence, the RNA therapeutics market is projected to witness strong long-term growth and become a cornerstone of next-generation drug development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

Vaccines
Drugs

By Type

mRNA Therapeutics
RNA Interference (RNAi) Therapeutics
Antisense Oligonucleotide (ASO) Therapeutics
Other Therapeutics

By Indication

Infectious Diseases
Rare Genetic Diseases/Hereditary Diseases
Other Indications

By End User

Hospitals and Clinics
Research Settings

COMPANIES PROFILED

Moderna Inc, Alnylam Pharmaceuticals Inc, Pfizer Inc, Novartis AG, Ionis Pharmaceuticals Inc, Sarepta Therapeutics Inc, Sanofi, Arrowhead Pharmaceuticals Inc, BioNTech SE, Orna Therapeutics, CRISPR Therapeutics, Silence Therapeutics, Astellas Pharma Inc, CureVac SE, Sirnaomics
We can customise the report as per your requirements.

Product Code: VMR112112419

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL RNA THERAPEUTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Product
4.2. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RNA THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Type
5.2. mRNA Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. RNA Interference (RNAi) Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Antisense Oligonucleotide (ASO) Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Other Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RNA THERAPEUTICS MARKET: BY INDICATION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Indication
6.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Rare Genetic Diseases/Hereditary Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RNA THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast End User
7.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Research Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RNA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Product
- 8.2.2 By Type
- 8.2.3 By Indication
- 8.2.4 By End User
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Product
- 8.3.2 By Type
- 8.3.3 By Indication
- 8.3.4 By End User
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Product
- 8.4.2 By Type
- 8.4.3 By Indication
- 8.4.4 By End User
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Product
- 8.5.2 By Type
- 8.5.3 By Indication
- 8.5.4 By End User
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Product
- 8.6.2 By Type
- 8.6.3 By Indication
- 8.6.4 By End User
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL RNA THERAPEUTICS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Company Profiles
- 10.2.1 Moderna Inc
- 10.2.2 Alnylam Pharmaceuticals Inc
- 10.2.3 Pfizer Inc
- 10.2.4 Novartis AG
- 10.2.5 Ionis Pharmaceuticals Inc
- 10.2.6 Sarepta Therapeutics Inc
- 10.2.7 Sanofi
- 10.2.8 Arrowhead Pharmaceuticals Inc
- 10.2.9 BioNTech SE
- 10.2.10 Orna Therapeutics
- 10.2.11 CRISPR Therapeutics
- 10.2.12 Silence Therapeutics
- 10.2.13 Astellas Pharma Inc
- 10.2.14 CureVac SE
- 10.2.15 Sirnaomics